Panagiotis A. Konstantinopoulos, MD, PhD, of Dana-Farber Cancer Institute, discusses his phase II study on the response to avelumab in microsatellite-stable and -instable recurrent or persistent endometrial cancer with a polymerase epsilon mutation (Abstract 5502).
Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California Los Angeles, discusses 3-year outcomes from the first phase III study to test a non-conventional regimen for the neoadjuvant and adjuvant treatment of HER2-positive breast cancer (Abstract 500).
Kerry A. Rogers, MD, of The Ohio State University, discusses a 3-year follow-up of phase Ib safety and efficacy findings with the selective BTK inhibitor acalabrutinib and the anti-CD20 monoclonal antibody obinutuzumab in patients with CLL (Abstract 7500).
Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, discusses data from an international cohort study on counseling women with breast cancer who have a BRCA mutation about the safety of becoming pregnant once they complete treatment (Abstract 11506).
Kim N. Chi, MD, of BC Cancer, discusses the first phase III findings from the TITAN study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen-deprivation therapy (Abstract 5006).
Miriam Knoll, MD, and Zachery Reichert, MD, PhD, discuss the FORCE trial, which is examining whether radiation can create a more durable response to systemic therapy, and whether using newer, more sensitive imaging technologies can improve outcomes (Abstract TPS5096).
